Swedencare AB (publ)

LSE:0ABG Stock Report

Market Cap: SEK 7.1b

Swedencare Valuation

Is 0ABG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ABG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0ABG (SEK44.46) is trading below our estimate of fair value (SEK135.94)

Significantly Below Fair Value: 0ABG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ABG?

Key metric: As 0ABG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0ABG. This is calculated by dividing 0ABG's market cap by their current earnings.
What is 0ABG's PE Ratio?
PE Ratio114.5x
EarningsSEK 62.10m
Market CapSEK 7.11b

Price to Earnings Ratio vs Peers

How does 0ABG's PE Ratio compare to its peers?

The above table shows the PE ratio for 0ABG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.4x
ANCR Animalcare Group
30.9x15.8%UK£143.1m
HIK Hikma Pharmaceuticals
17.8x11.2%UK£4.0b
EAH ECO Animal Health Group
42x34.2%UK£44.0m
ERGO Ergomed
46.7x14.2%UK£701.1m
0ABG Swedencare
114.5x64.2%SEK 7.1b

Price-To-Earnings vs Peers: 0ABG is expensive based on its Price-To-Earnings Ratio (114.5x) compared to the peer average (30.3x).

Price to Earnings Ratio vs Industry

How does 0ABG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0ABG 114.5xIndustry Avg. 20.6xNo. of Companies7PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0ABG is expensive based on its Price-To-Earnings Ratio (114.5x) compared to the European Pharmaceuticals industry average (20.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0ABG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ABG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio114.5x
Fair PE Ratio43.7x

Price-To-Earnings vs Fair Ratio: 0ABG is expensive based on its Price-To-Earnings Ratio (114.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0ABG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 44.46
SEK 58.67
+32.0%
6.6%SEK 64.00SEK 55.00n/a3
Nov ’25SEK 45.80
SEK 58.67
+28.1%
6.6%SEK 64.00SEK 55.00n/a3
Oct ’25SEK 43.46
SEK 63.00
+45.0%
1.6%SEK 64.00SEK 62.00n/a2
Sep ’25SEK 40.78
SEK 63.00
+54.5%
1.6%SEK 64.00SEK 62.00n/a2
Aug ’25SEK 45.88
SEK 63.00
+37.3%
1.6%SEK 64.00SEK 62.00n/a2
Jul ’25SEK 58.05
SEK 67.00
+15.4%
4.5%SEK 70.00SEK 64.00n/a2
Jun ’25SEK 57.50
SEK 67.00
+16.5%
4.5%SEK 70.00SEK 64.00n/a2
May ’25SEK 56.20
SEK 67.00
+19.2%
4.5%SEK 70.00SEK 64.00n/a2
Apr ’25SEK 64.64
SEK 68.00
+5.2%
5.9%SEK 72.00SEK 64.00n/a2
Mar ’25SEK 55.11
SEK 68.00
+23.4%
5.9%SEK 72.00SEK 64.00n/a2
Feb ’25SEK 62.17
SEK 59.50
-4.3%
7.6%SEK 64.00SEK 55.00n/a2
Jan ’25SEK 61.12
SEK 50.00
-18.2%
10.0%SEK 55.00SEK 45.00n/a2
Dec ’24SEK 59.00
SEK 50.00
-15.3%
10.0%SEK 55.00SEK 45.00n/a2
Nov ’24SEK 44.00
SEK 50.00
+13.6%
10.0%SEK 55.00SEK 45.00SEK 45.802
Oct ’24SEK 40.86
SEK 49.50
+21.1%
9.1%SEK 54.00SEK 45.00SEK 43.462
Sep ’24SEK 46.90
SEK 49.50
+5.5%
9.1%SEK 54.00SEK 45.00SEK 40.782
Aug ’24SEK 46.20
SEK 44.50
-3.7%
21.3%SEK 54.00SEK 35.00SEK 45.882
Jul ’24SEK 38.23
SEK 44.50
+16.4%
21.3%SEK 54.00SEK 35.00SEK 58.052
Jun ’24SEK 43.03
SEK 44.50
+3.4%
21.3%SEK 54.00SEK 35.00SEK 57.502
May ’24SEK 32.29
SEK 42.00
+30.1%
31.0%SEK 55.00SEK 29.00SEK 56.202
Apr ’24SEK 25.35
SEK 47.50
+87.4%
26.3%SEK 60.00SEK 35.00SEK 64.642
Mar ’24SEK 26.80
SEK 47.25
+76.3%
27.0%SEK 60.00SEK 34.50SEK 55.112
Feb ’24SEK 36.15
SEK 54.75
+51.4%
37.0%SEK 75.00SEK 34.50SEK 62.172
Jan ’24SEK 30.91
SEK 58.00
+87.6%
29.3%SEK 75.00SEK 41.00SEK 61.122
Dec ’23SEK 34.99
SEK 58.00
+65.7%
29.3%SEK 75.00SEK 41.00SEK 59.002

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£172.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.35

7D

7.7%

1Y

-14.5%

Regeneron Pharmaceuticals

US$82.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$760.78

7D

-7.0%

1Y

-4.4%